Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

One of the most frustrating problems faced by doctors who treat pancreatic cancer is the lack of effective therapeutic options. More than 38,000 people in the United States die of the disease each year, and new drugs and treatments are desperately needed.

8 Nov 2010

Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders

Synergy Pharmaceuticals, Inc. a developer of new drugs to treat gastrointestinal disorders (GI) and diseases, announced today that it has been awarded a $244,479 grant under the Qualifying Therapeutic Discovery Project (QTDP) program to aid the Company in its development of plecanatide currently in clinical development to treat gastrointestinal disorders.

8 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Jefferson professor named 'Physician of the Year' by CancerCare

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently named 'Physician of the Year' by CancerCare, a national nonprofit organization that provides free, professional support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. Dr. Mitchell is being honored for her work in gastrointestinal malignancies.

4 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.

2 Nov 2010

Global Health Partner third quarter revenue increases 17% to SEK 108.8 million

Global Health Partner AB: Revenues increased by 17 percent to SEK 108.8 million (93.3). The operating result amounted to SEK -4.1 million (-13.1)

2 Nov 2010

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation (IBS-C).

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Pasteurized human milk is a recommended alternative for hospitalized sick newborns when their own mother's milk is not available, according to a new statement by the Canadian Paediatric Society. The statement, published today in Paediatrics & Child Health, says that human milk banking in Canada should be encouraged and promoted.

1 Nov 2010

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.

1 Nov 2010

Intentional foreign body ingestion results in over $2 million hospital costs: Study

A new study from Rhode Island Hospital found that 33 individuals were responsible for 305 cases of medical intervention to remove foreign bodies that were intentionally swallowed, resulting in more than $2 million in estimated hospital costs. The findings appear in the November issue of Clinical Gastroenterology and Hepatology.

1 Nov 2010

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

The race of liver donors may affect recurrent hepatitis C in patients after liver transplant, according to a study by Henry Ford Hospital. Patients receiving white cadaveric donor grafts had significantly more aggressive recurrent hepatitis C than those receiving grafts from African-American donors regardless of recipient race, says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

XenoPort third quarter net loss decreases to $19.9 million

Study suggests bacterial products contribute to autoimmune diseases

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Jefferson professor named 'Physician of the Year' by CancerCare

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Global Health Partner third quarter revenue increases 17% to SEK 108.8 million

Positive results from linaclotide Phase 3 trial in patients with IBS-C

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Intentional foreign body ingestion results in over $2 million hospital costs: Study

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Microbiology eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in